|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Basic and Translational Investigations |
Children's Research Institute, Children's National Medical Center, Washington, DC 20010 (B.R.R., H.Z.); Department of Pediatrics, Institute for Biomedical Sciences, The George Washington University Medical Center, Washington, DC 20037 (P.H.C.); USA
2 Address correspondence to Brian R. Rood, Division of Hematology/Oncology, Children's National Medical Center, 111 Michigan Ave., NW, Washington, DC 20010, USA (Brood{at}CNMC.org).
Abstract
DNA methylation and epigenetic inactivation of the O6-methylguanine methyltransferase (MGMT) gene induces MGMT deficiency, reducing the tumor cell's DNA repair capacity and increasing its susceptibility to alkylating chemotherapeutic agents. Consequently, adult patients whose tumors are deficient in MGMT have better outcomes with alkylator chemotherapy, and MGMT methylation has been proposed as a screening marker of deficient tumors. In order to test the feasibility of this approach for medulloblastoma, a common brain tumor in children, we determined the methylation status, mRNA expression pattern, and protein expression of MGMT in a panel of clinical specimens. Methylation-specific polymerase chain reaction analysis revealed methylation of MGMT in 28 of 37 tumor samples. Quantitative real-time reverse transcriptase-polymerase chain reaction showed a range of expression of MGMT mRNA varying more than 20-fold. However, there was no correlation found between MGMT methylation and mRNA expression. Immunohistochemistry demonstrated that all tumors were immunoreactive for MGMT in the nucleus of the medulloblastoma cells in a heterogeneous pattern. The intercell variability of MGMT complement explained the discordance between methylation and expression. Therefore, MGMT methylation as determined by methylation-specific polymerase chain reaction cannot be used as a marker for MGMT deficiency in medulloblastoma. Further, these findings support the use of pharmacological MGMT depletion as a rational approach for intensification of alkylator chemotherapy in the treatment of medulloblastoma.
References
Bae, S.I., Lee, H.S., Kim, S.H., and Kim, W.H. (2002) Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers. Br. J. Cancer 86,1888 -1892.[CrossRef][Medline]
Belanich, M., Pastor, M., Randall, T., Guerra, D., Kibitel, J.,
Alas, L., Li, B., Citron, M., Wasserman, P., White, A., Eyre, H., Jaeckle, K.,
Schulman, S., Rector, D., Prados, M., Coons, S., Shapiro, W., and Yarosh, D.
(1996) Retrospective study of the correlation between the DNA
repair protein alkyltransferase and survival of brain tumor patients treated
with carmustine. Cancer Res.
56,783
-788.
Bobola, M.S., Berger, M.S., Ellenbogen, R.G., Roberts, T.S., Geyer,
J.R., and Silber, J.R. (2001) O6-Methylguanine-DNA
methyltransferase in pediatric primary brain tumors: Relation to patient and
tumor characteristics. Clin. Cancer Res.
7, 613-619.
Costello, J.F., Futscher, B.W., Tano, K., Graunke, D.M., and
Pieper, R.O. (1994) Graded methylation in the promoter and body
of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT
expression in human glioma cells. J. Biol. Chem.
269,17228
-17237.
Danam, R.P., Qian, X.C., Howell, S.R., and Brent, T.P. (1999) Methylation of selected CpGs in the human O6-methylguanine-DNA methyltransferase promoter region as a marker of gene silencing. Mol. Carcinog. 24, 85-89.[CrossRef][Web of Science][Medline]
Deng, C.J., Xie, D.W., Capasso, H., Zhao, Y.J., Wang, L.D., and Hong, J.Y. (1999) Genetic polymorphism of human O6-alkylguanine-DNA alkyltransferase: Identification of a missense variation in the active site region. Pharmacogenetics 9, 81-87.[Web of Science][Medline]
Edara, S., Kanugula, S., and Pegg, A.E. (1999)
Expression of the inactive C145A mutant human O6-alkylguanine-DNA
alkyltransferase in E. coli increases cell killing and mutations by
N-methyl-N'-nitro-N-nitrosoguanidine.
Carcinogenesis 20,103
-108.
Esteller, M., Hamilton, S.R., Burger, P.C., Baylin, S.B., and
Herman, J.G. (1999) Inactivation of the DNA repair gene
O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a
common event in primary human neoplasia. Cancer Res.
59,793
-797.
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S.N.,
Hidalgo, O.F., Vanaclocha, V., Baylin, S.B., and Herman, J.G.
(2000a) Inactivation of the DNA-repair gene MGMT and the clinical
response of gliomas to alkylating agents. N. Engl. J.
Med. 343,1350
-1354.
Esteller, M., Toyota, M., Sanchez-Cespedes, M., Capella, G.,
Peinado, M.A., Watkins, D.N., Issa, J.P., Sidransky, D., Baylin, S.B., and
Herman, J.G. (2000b) Inactivation of the DNA repair gene
O6-methylguanine-DNA methyltransferase by promoter hypermethylation is
associated with G to A mutations in K-ras in colorectal tumorigenesis.
Cancer Res. 60,2368
-2371.
Fornace, A.J., Jr., Papathanasiou, M.A., Hollander, M.C., and
Yarosh, D.B. (1990) Expression of the O6-methylguanine-DNA
methyltransferase gene MGMT in MER+ and MER-human tumor cells.
Cancer Res. 50,7908
-7911.
Frommer, M., McDonald, L.E., Millar, D.S., Collis, C.M., Watt, F.,
Grigg, G.W., Molloy, P.L., and Paul, C.L. (1992) A genomic
sequencing protocol that yields a positive display of 5-methylcytosine
residues in individual DNA strands. Proc. Natl. Acad. Sci.
USA 89,1827
-1831.
He, X.M., Ostrowski, L.E., von Wronski, M.A., Friedman, H.S.,
Wikstrand, C.J., Bigner, S.H., Rasheed, A., Batra, S.K., Mitra, S., Brent,
T.P., and Bigner, D.D. (1992) Expression of O6-methylguanine-DNA
methyltransferase in six human medulloblastoma cell lines. Cancer
Res. 52,1144
-1148.
Herfarth, K.K., Brent, T.P., Danam, R.P., Remack, J.S., Kodner, I.J., Wells, S.A., Jr., and Goodfellow, P.J. (1999) A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol. Carcinog. 24,90 -98.[CrossRef][Web of Science][Medline]
Herman, J.G., Graff, J.R., Myohanen, S., Nelkin, B.D., and Baylin,
S.B. (1996) Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc. Natl. Acad. Sci.
USA 93,9821
-9826.
Hongeng, S., Brent, T.P., Sanford, R.A., Li, H., Kun, L.E., and
Heideman, R.L. (1997) O6-Methylguanine-DNA methyltransferase
protein levels in pediatric brain tumors. Clin. Cancer
Res. 3,2459
-2463.
Jaeckle, K.A., Eyre, H.J., Townsend, J.J., Schulman, S., Knudson, H.M., Belanich, M., Yarosh, D.B., Bearman, S.I., Giroux, D.J., and Schold, S.C. (1998) Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: A Southwest Oncology Group study. J. Clin. Oncol. 16,3310 -3315.[Abstract]
Kanugula, S., Goodtzova, K., Edara, S., and Pegg, A.E. (1995) Alteration of arginine-128 to alanine abolishes the ability of human O6-alkylguanine-DNA alkyltransferase to repair methylated DNA but has no effect on its reaction with O6-benzylguanine. Biochemistry 34,7113 -7119.[CrossRef][Medline]
NIH. National Institutes of Health (2003) GenBank.National Center for Biotechnology Information (available at http://www.ncbi.nlm.nih.gov/Genbank).
Packer, R.J., Meadows, A.T., Rorke, L.B., Goldwein, J.L., and D'Angio, G. (1987) Long-term sequelae of cancer treatment on the central nervous system in childhood. Med. Pediatr. Oncol. 15,241 -253.[Web of Science][Medline]
Packer, R.J., Sutton, L.N., Atkins, T.E., Radcliffe, J., Bunin, G.R., D'Angio, G., Siegel, K.R., and Schut, L. (1989) A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. J. Neurosurg. 70,707 -713.[Web of Science][Medline]
Packer, R.J., Sutton, L.N., Elterman, R., Lange, B., Goldwein, J., Nicholson, H.S., Mulne, L., Boyett, J., D'Angio, G., Wechsler-Jentzsch, K., Reaman, G., Cohen, B.H., Bruce, D.A., Rorke, L.B., Molloy, P., Ryan, J., Lafond, D., Evans, A.E., and Schut, L. (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J. Neurosurg. 81,690 -698.[Web of Science][Medline]
Pieper, R.O., Lester, K.A., and Fanton, C.P. (1999)
Confluence-induced alterations in CpG island methylation in cultured normal
human fibroblasts. Nucleic Acids Res.
27,3229
-3235.
Qian, X.C., and Brent, T.P. (1997) Methylation hot
spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA
methyltransferase gene. Cancer Res.
57,3672
-3677.
Silber, J.R., Mueller, B.A., Ewers, T.G., and Berger, M.S.
(1993) Comparison of O6-methylguanine-DNA methyltransferase
activity in brain tumors and adjacent normal brain. Cancer
Res. 53,3416
-3420.
Silber, J.R., Bobola, M.S., Ghatan, S., Blank, A., Kolstoe, D.D.,
and Berger, M.S. (1998) O6-methylguanine-DNA methyltransferase
activity in adult gliomas: Relation to patient and tumor characteristics.
Cancer Res. 58,1068
-1073.
Srivenugopal, K.S., Shou, J., Mullapudi, S.R., Lang, F.F., Jr.,
Rao, J.S., and Ali-Osman, F. (2001) Enforced expression of
wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA
methyltransferase gene in human tumor cells and enhances their sensitivity to
alkylating agents. Clin. Cancer Res.
7,1398
-1409.
Watts, G.S., Pieper, R.O., Costello, J.F., Peng, Y.M., Dalton, W.S., and Futscher, B.W. (1997) Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol. Cell Biol. 17,5612 -5619.[Abstract]
Yuan, Q., Matsumoto, K., Nakabeppu, Y., and Iwaki, T. (2003) A comparative immunohistochemistry of O6-methylguanine-DNA methyltransferase and p53 in diffusely infiltrating astrocytomas. Neuropathology 23,203 -209.[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Spiegl-Kreinecker, C. Pirker, M. Filipits, D. Lotsch, J. Buchroithner, J. Pichler, R. Silye, S. Weis, M. Micksche, J. Fischer, et al. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients Neuro Oncology, October 15, 2009; (2009) nop003v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. MELLAI, V. CALDERA, L. ANNOVAZZI, A. CHIO, M. LANOTTE, P. CASSONI, G. FINOCCHIARO, and D. SCHIFFER MGMT Promoter Hypermethylation in a Series of 104 Glioblastomas Cancer Genomics Proteomics, July 1, 2009; 6(4): 219 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Maxwell, S. P. Johnson, J. A. Quinn, R. E. McLendon, F. Ali-Osman, A. H. Friedman, J. E. Herndon II, K. Bierau, J. Bigley, D. D. Bigner, et al. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol. Cancer Ther., October 1, 2006; 5(10): 2531 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brell, A. Tortosa, E. Verger, J. M. Gil, N. Vinolas, S. Villa, J. J. Acebes, L. Caral, T. Pujol, I. Ferrer, et al. Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas Clin. Cancer Res., July 15, 2005; 11(14): 5167 - 5174. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
